# Yisite Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yisite-biotechnology

- Industry: Chemicals
- Headquarters: Hangzhou, China
- Latest round: Series A (Mar 7, 2025)
- Investors on record: 1

## About

Established in 2018 and based in Hangzhou, China, Yisite Biotechnology operates as a biotechnology company that mainly provides non-animal source DHA (Docosahexaenoic Acid) and EPA (Eicosapentaenoic Acid) product solutions. In March 2025, the company closed series A funding from new investor Goldport Capital.

The company uses enzyme engineering and metabolic engineering technologies to provide synthetic biology specialty oil raw materials. The products are divided into algae oil series and fish oil series. The algae oil series includes DHA and EPA products derived from algae oil, which can provide natural high-purity non-animal product solutions. The fish oil series includes fish oil and DHA and EPA products derived from fish oil. The company also provides products such as diglycerides and structured esters. The products can be used in the fields of food, pharmaceutical raw materials, and functional food raw materials.

The company generates revenue by providing synthetic biology specialty oil raw materials such as DHA and EPA products.

The company will use the series A funding for the construction of thousand-ton-level DHA and EPA production capacity, technology iteration, and global market expansion.

## Funding rounds

- Series A, Mar 7, 2025 — Goldport Capital

## Investors

- Goldport Capital (https://capitalatlas.ai/funds/goldport-capital) — Series A